Skip to main content

Table 2 Work Productivity and Activity Index for Spondyloarthritis scores at baseline for biologic disease-modifying anti-rheumatic drug-naïve patients (COAST-V study) across treatment arms

From: Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Work productivity and activity measures Treatment arms
PBO (N = 87) ADA (N = 90) IXE Q4W (N = 81) IXE Q2W (N = 83)
Absenteeisma
 Nx 57 71 61 57
 Mean (SD) 7.2 (14.8) 13.6 (27.2) 8.0 (20.4) 14.1 (27.9)
Presenteeisma
 Nx 57 66 59 53
 Mean (SD) 61.4 (19.5) 53.2 (21.9) 57.1 (21.3) 54.9 (21.5)
Overall work impairmenta
 Nx 57 66 59 53
 Mean (SD) 63.2 (20.3) 55.0 (23.3) 58.7 (21.8) 57.4 (22.8)
Activity impairment
 Nx 87 90 81 83
 Mean (SD) 62.4 (20.5) 58.2 (20.5) 58.8 (18.1) 61.0 (20.7)
  1. ADA 40 mg adalimumab every 2 weeks, IXE Q2W 80 mg ixekizumab every 2 weeks, IXE Q4W 80 mg ixekizumab every 4 weeks, N number of patients in the treatment group, Nx number of patients in the analysis subgroup, PBO placebo
  2. aAbsenteeism, presenteeism, and overall work impairment were measured in patients reporting part- or full-time work